Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials in Houston, Texas

8 studies are recruiting for pancreatic ductal adenocarcinoma (pdac) in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   49 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07491445 on ClinicalTrials.gov

2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

   This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   29 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07644559 on ClinicalTrials.gov

3. Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

   The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Excel Diagnostics & Nuclear Oncology Center, Houston, Texas

   Run by

   Radiomedix, Inc.

   See if you can join NCT07733674 on ClinicalTrials.gov

4. EUS-RFA PANCARDINAL-1 Trial

   The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Hermann Hospital, Houston, Texas

   Run by

   The University of Texas Health Science Center, Houston

   See if you can join NCT04990609 on ClinicalTrials.gov

5. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

   This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   38 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06026410 on ClinicalTrials.gov

6. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

   This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas, MD Anderson Cancer Center, Houston, Texas

   Locations

   17 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06040541 on ClinicalTrials.gov

7. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

   Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   21 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT05379985 on ClinicalTrials.gov

8. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

   This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   6 in total

   Run by

   Tanabe Pharma America, Inc.

   See if you can join NCT06943521 on ClinicalTrials.gov